ATI RN
ATI Pharmacology Proctored Exam 2019
1. A healthcare professional is preparing to administer Filgrastim for the first time to a client who has just undergone a bone marrow transplant. Which of the following interventions is appropriate?
- A. Administer subcutaneously in a large muscle mass to prevent injury.
- B. Ensure that the medication is kept at room temperature until just prior to administration.
- C. Invert vial gently to mix well before withdrawing dose.
- D. Discard vial after removing one dose of the medication.
Correct answer: D
Rationale: The correct intervention when preparing to administer Filgrastim is to discard the vial after removing one dose of the medication. This practice helps prevent contamination and ensures the medication's effectiveness. Reusing the vial can lead to contamination and compromise the sterility of the medication, putting the client at risk. Therefore, it is crucial to follow proper aseptic technique and discard the vial after withdrawing the prescribed dose.
2. A healthcare professional is preparing to administer a dose of Hydromorphone IV to a client. Which of the following actions should the healthcare professional take?
- A. Administer the medication over 5 minutes.
- B. Administer a dose of Naloxone prior to giving the Hydromorphone.
- C. Assess the client's blood pressure prior to administration.
- D. Inject the medication into the client's subcutaneous tissue.
Correct answer: A
Rationale: The healthcare professional should administer IV Hydromorphone slowly over 5 minutes to reduce the risk of hypotension and respiratory depression. Rapid administration can lead to adverse effects due to its potency. Choice B is incorrect because Naloxone is used as an antidote for opioid overdose, not routinely administered with Hydromorphone. Choice C is important but not specific to the administration of Hydromorphone. Choice D is incorrect as Hydromorphone is intended for intravenous use, not subcutaneous injection.
3. A nurse is caring for a client in an outpatient facility who has been taking Acarbose for type 2 Diabetes Mellitus. Which of the following laboratory tests should the nurse plan to monitor?
- A. WBC
- B. Serum potassium
- C. Platelet count
- D. Liver function test
Correct answer: D
Rationale: The correct answer is D, Liver function test. Acarbose can cause liver toxicity when taken long-term. Monitoring liver function tests periodically is essential to assess for any potential liver damage. Choices A, B, and C are incorrect because Acarbose does not directly impact white blood cell count, serum potassium levels, or platelet count.
4. What is the correct definition of drug absorption?
- A. Movement of a drug from the site of administration to various tissues of the body
- B. Describes the absorption, distribution, metabolism, and excretion of drugs
- C. These types of drugs can be taken over the counter
- D. This addresses how various drugs affect different forms of the body
Correct answer: A
Rationale: The correct definition of drug absorption is the movement of a drug from the site of administration into various tissues of the body. It is the process by which a drug is taken up and enters the systemic circulation. Choice B describes the pharmacokinetics of drugs, including absorption, distribution, metabolism, and excretion, but it is not a specific definition of drug absorption. Choice C is unrelated to drug absorption, as it refers to over-the-counter drugs. Choice D is too vague and does not specifically address the process of drug absorption.
5. A client has a new prescription for Ondansetron for nausea and vomiting associated with chemotherapy. Which of the following statements should the nurse include?
- A. Take this medication one hour before chemotherapy.
- B. You may experience a headache while taking this medication.
- C. Increase your intake of potassium while taking this medication.
- D. This medication may cause temporary hearing loss.
Correct answer: B
Rationale: The correct statement the nurse should include is that the client may experience a headache while taking Ondansetron. Headache is a common side effect of this medication, and clients need to be informed about this potential adverse reaction to enhance their understanding and management of side effects. The other statements are incorrect because Ondansetron is usually taken 30 minutes before chemotherapy, not one hour before (choice A). There is no specific need to increase potassium intake while taking Ondansetron (choice C), and temporary hearing loss is not a common side effect associated with this medication (choice D).
Similar Questions
Access More Features
ATI RN Basic
$69.99/ 30 days
- 5,000 Questions with answers
- All ATI courses Coverage
- 30 days access
ATI RN Premium
$149.99/ 90 days
- 5,000 Questions with answers
- All ATI courses Coverage
- 30 days access